US › Healthcare

Sophia Genetics SA (SOPH)

US · Healthcare · Health Information Services

$6.84+20.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$21.7M
Revenue YoY
+22.0%
Net profit
$-19.3M
Profit YoY
-11.1%
EPS
$-0.19
EPS estimate
$-0.24
Net margin
-89.1%

EPS came in at -0.19 against a street estimate of -0.24 — a beat of 20.8%.

Key statistics

Market cap
$475.7M
Forward P/E
0.0
P/B
10.41
Book value
$0.64
EPS (TTM)
$-1.18
52-week high
$6.77
52-week low
$2.92
50-day MA
$5.45
200-day MA
$4.95
Beta
0.96

Analyst view

Analysts rate Sophia Genetics SA a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $9.00.

Shareholding

Insiders
7.03%
Institutions
48.00%

Largest institutional holders

FundStake
Generation Investment Management LLP8.09%
Akre Capital Management, LLC4.43%
Banque Pictet & Cie SA2.63%
Soleus Capital Management, L.P.2.21%
Royce & Associates, LP2.17%
Principal Financial Group Inc1.68%
Alta Wealth Advisors LLC1.68%
Kennedy Capital Management Inc1.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sophia Genetics SA — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.